Rocket Pharmaceuticals' CEO Dr. Gaurav Shah on FDA's Clinical Holds on Gene Therapy Trials
- Author
- Erin Harris
- Published
- Thu 31 Mar 2022
- Episode Link
- None
We love to hear from our listeners. Send us a message.
Rocket Pharmaceuticals CEO Dr. Gaurav Shah offers his take on why gene therapy developers have been plagued by clinical holds, whether the FDA’s AAV-focused CTGTAC meeting's takeaways will hold up throughout 2022, and more.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
